CHRONIC PAIN MARKET ANALYSIS
Global chronic pain market is estimated to be valued at USD 72.10 Bn in 2024 and is expected to reach USD 115.51 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031. Increasing geriatric population who are more prone to chronic diseases and various innovations in pain management therapeutics can drive the market growth during the forecast period.
To learn more about this report, request sample copy
Increasing prevalence of chronic diseases
Rising burden of chronic diseases can drive the market growth. Longer life expectancy and evolving lifestyle trends have largely contributed to this global epidemic. Chronic diseases such as diabetes, arthritis, cardiovascular diseases, and others which were earlier seen as disorders specific to developed nations are now spreading to low- and middle-income countries at an alarming rate.
Due to unhealthy diet, physical inactivity, and tobacco use, more people are becoming susceptible to these chronic conditions at younger ages. Developing countries undergoing nutrition transition are witnessing increase in obesity levels in their populations. This has further accelerated the occurrence of diabetes, joint problems and other chronic diseases. Even though healthcare infrastructure has been improving in these regions, management of chronic diseases poses significant challenges due to limited resources and awareness.
Chronic diseases often coexist with other comorbidities compounding the severity of conditions in affected patients. Diabetic patient is likely to develop hypertension, kidney complications or cardiovascular problems, if diagnosis and treatment is delayed. Mismanagement or lack of support also raises psycho-social issues for people living with chronic pain over long periods. All these factors have contributed to chronic diseases collectively becoming one of the leading causes of morbidity in both developed and developing parts of the world.
Given their irreversible and lifelong nature, the personal and economic burden associated with chronic diseases escalate with time. As more people are diagnosed, there has been increase in need for improved diagnostic methods, safer and cost-effective drugs, rehab measures and assistive devices. Organizations working in the area of chronic disease prevention have strived to raise awareness and initiate campaigns for behavioral change. However, pharmacological interventions remain critical for effective management of existing cases and alleviation of chronic pain symptoms.
Get actionable strategies to beat competition: Get instant access to report
Increasing awareness about chronic pain management
Rising awareness regarding chronic pain as a major health issue can drive the market growth. Chronic pain patients now have more resources to understand their condition and seek appropriate support. Advocacy efforts by survivors, medical professionals and policymakers have reduced the stigma around chronic pain. Regular conversations in media and online health communities have normalized discussions on living with and management of chronic pain.
Caregivers are more proactive in identifying signs and symptoms at early stages. People are also adopting preventive measures to dodge risk factors and lifestyle triggers that can potentially induce chronic pain. Healthcare systems worldwide have stepped up to acknowledge pain as the fifth vital sign along with initiatives to improve pain assessment practices. Treatment guidelines now focus on more holistic and multidisciplinary approaches instead of just symptomatic relief. Significant progress has been made to include alternative therapies, educate on safer usage of opioids, emphasize importance of rehab and psyche support.
Patients experiencing persistent pain are no longer expected to simply live with pain. Rising awareness levels have boosted demand for advanced pain relief options whether through drugs, supplements, medical devices or surgeries. Individuals are empowered to make informed choices, try out new lines of treatment and follow up regularly to ensure continuum of care. Various studies show people are more willing to bear out-of-pocket expenses especially when quality of life can be improved.
Key Takeaways from Analyst:
Global chronic pain market growth is driven by growing geriatric population who are more susceptible to chronic pain conditions. Rising lifestyle diseases such as arthritis and growing acceptance of pain therapies also boosts demand for chronic pain treatments.
Stringent regulations for approval of new chronic pain drugs has made the development process long and costly. This acts as a restraint for smaller players and discourages R&D investments. Moreover, issues related to drug abuse and addiction associated with some pain therapies further complicate the treatment landscape.
North America currently dominates the chronic pain market, owing to high awareness and well-established healthcare systems. However, Asia Pacific is expected to emerge as the fastest growing region due to rising incomes, healthcare reforms and increasing focus on pain management. Favorable shifts from opioids to alternate options like cannabinoids can open new avenues for pharmaceutical companies.
Market Challenge - High treatment costs
Global chronic pain market growth can be hampered due to high treatment costs associated with chronic pain medications and therapies. As chronic pain conditions often require long-term or lifetime management, the costs of medications, physician visits, therapies and procedures can accumulate significantly over time for patients, providers and payers. Indirect costs of chronic pain such as loss of productivity at work and lower quality of life also places a huge economic burden on individuals and society. Patients may have difficulties affording and adhering to prescribed treatment regimens due to their high costs. Payers and healthcare systems also struggle to manage the expenses of chronic pain management in a cost-effective and sustainable manner. High treatment expenditures can render chronic pain as an unsustainable healthcare issue from an economic perspective. Unless costs are controlled through more efficient care delivery and cheaper treatment alternatives, it will continue to strain budgets and be a barriers to effective pain relief.
Market Opportunity: New Treatment Options and Technologies
Development of new and innovative treatment options as well as technologies can offer market growth opportunities. There has been significant research underway to discover novel drugs and drug formulations that can better target the specific mechanisms underlying different chronic pain conditions with improved safety, tolerability and effectiveness profiles. Alternative therapies such as neural stimulation devices, gene therapies and other interventions are also being investigated, which may help manage chronic pain in new ways. New technologies allowing precision diagnostics, less invasive procedures and remote or home-based care delivery can enhance chronic pain management. Their ability to lower costs of care while maintaining or improving outcomes can address one of the key challenges around high treatment expenditures. Investments into research for new treatments and technologies have the potential to transform chronic pain management.
Discover high revenue pocket segments and roadmap to it: Get instant access to report
By Drug Class - Rising Dependence on Opioids
In terms of drug class, opioids segment is estimated to contribute the highest market share of 40% in 2024, owing to their widespread and long-term use for treating chronic pain conditions. Opioids are a class of drugs that work by binding to opioid receptors in the brain and spinal cord to reduce the intensity of pain signals reaching the brain. Their ability to effectively relieve both acute and chronic pain has led to increasing dependence on these drugs.
Inadequate treatment options otherwise available for chronic conditions causing severe ongoing pain can boost usage of opioids. Diseases like arthritis, lower back pain and cancer often have no cure and severely impact quality of life. While over-the-counter painkillers provide some relief, these are not strong enough for moderate to severe chronic pain. This has made opioids as the most potent pharmacological solution licensed for long-term pain management. Furthermore, lack of access to alternative treatments like physical therapy and cognitive behavioral therapy in many countries has made opioids as the mainstay treatment.
Aggressive marketing of prescription opioids by major pharmaceutical companies can also drive the segment growth. Claims that opioids were rarely addictive even with long-term usage led to surge in prescriptions by physicians and reliance on them by patients. While regulations have been tightened, a dependence on opioids for chronic pain management was already entrenched in medical practice and among patients. Socio-economic challenges can increase vulnerability to opioid misuse.
By Indication - Neuropathic Pain Segment Dominates
In terms of indication, neuropathic pain segment is estimated to contribute the highest market share of 35% in 2024, owing to its diverse causes and complex pathophysiology. Neuropathic pain occurs due to lesions or diseases affecting the somatosensory nervous system. It is associated with numerous conditions like diabetes, shingles, spinal cord injuries, and trigeminal neuralgia and cancer treatments. Neuropathic pain is often chronic in nature and notoriously difficult to treat due to abnormal hyperexcitability within the nervous system.
The wide range of diseases capable of causing neuropathic changes means it affects a vast population globally. With rising obesity levels and increasing life expectancy, there has been increase in neuropathic pain indications linked to diabetes and neural injuries. Moreover, longer survival rates of cancer patients means more patients experiencing chemotherapy-induced peripheral neuropathy. Their symptoms like burning sensations, allodynia and hyperalgesia demand tailored pharmaceutical management.
Neuropathic pain has proven highly recalcitrant to conventional analgesics due to its unusual pathophysiology. Effective treatment requires drugs specifically developed to target neuronal pathways rather than just general pain relief. The heterogeneity of neuropathic conditions necessitates a wide armamentarium of different drugs classes beyond just NSAIDs and opioids. This has boosted the dominance of the neuropathic pain segment, which depends greatly on newer anticonvulsants, antidepressants and other adjunctive therapies.
By Application - Musculoskeletal Segment Dominates
In terms of application, musculoskeletal segment is estimated to contribute the highest market share of 52% in 2024, due to an aging global population and rising rates of obesity. Musculoskeletal disorders encompass conditions affecting bones, joints, ligaments, tendons and muscles. Chronic pain is a cardinal symptom in arthritis, back injuries, osteoporosis and various degenerative joint diseases.
Advancing age itself is among the strongest risk factors for musculoskeletal complaints and their associated pain. As life expectancy increases worldwide, there will be rise in burden of chronic joint pain caused by age-related changes. Rising obesity prevalence compounds the issue - excessive weight puts stress joints like knees, worsens arthritis severity and frequently causes chronic lower back problems. Developing countries experiencing rapid economic growth and lifestyle shifts to high-calorie diets are now grappling with an obesity pandemic.
Musculoskeletal conditions often require long-term management rather than short-term relief of an episode. Their chronic, degenerative nature means pain medications must deliver efficacious relief without serious adverse effects over many recurring flare-ups. Furthermore, musculoskeletal pain varies widely in location and character necessitating diverse pharmacologic options. This drives dependence on multiple drug classes across antipsychotics, antidepressants, NSAIDs and others for effective polypharmacy treatment regimens tailored to each patient.
To learn more about this report, request sample copy
North America dominates the global chronic pain market with an estimated market share of 40.3% in 2024, owing to strong industry presence and its advanced healthcare infrastructure. The U.S. accounts for the largest share in the region due to growing acceptance of pain therapeutics and rising awareness levels among patients and healthcare providers regarding treatment options. Innovation is high among pharmaceutical companies in the region to develop novel drug delivery systems as well as combination therapies to tackle chronic pain disorders more effectively. This has ensured continuous launches of patented drugs that command premium pricing.
Europe chronic pain market follows North America in terms of size as countries like Germany, U.K., France and Spain are highly developed with robust healthcare systems. Generic medications have significant penetration but branded drugs still contribute substantially to the regional revenues. However, pricing pressure and healthcare budget constraints in certain nations may impact industry profits. Moreover, exports from emerging Eastern economies offer cost-competitive alternatives.
Asia Pacific region has emerged as the fastest growing chronic pain market. Rapid economic expansion across countries like China, India and South Korea has raised disposable incomes as well as boosted healthcare spending. Growing medical tourism arising from affordability of treatments in these Asia Pacific nations benefits domestic manufacturers.
Awareness regarding pain management is increasing and several regional players have entered deals with multinational corporations to gain from technology and expertise transfer. While China dominates the APAC market currently, India is fast catching up due to its large population size, lower costs of operations and production, and initiatives of the government to promote generic medicines manufacturing. Declining dependence on imports and increasing regional availability of patented, generic as well as biosimilar drugs bodes well for long-term prospects of chronic pain management in the Asia Pacific region.
Chronic Pain Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 72.10 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 7% | 2031 Value Projection: | US$ 115.51 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Pfizer Inc., Johnson & Johnson, GlaxoSmithKline PLC, Bayer AG, Novartis AG, Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Medtronic plc, AstraZeneca PLC, Becton, Dickinson and Company, AbbVie Inc., Horizon Therapeutics, Mallinckrodt Pharmaceuticals, Zynerba Pharmaceuticals, Neurocrine Biosciences, Sorrento Therapeutics, and Cypress Pharmaceutical |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Global chronic pain market includes the sale of treatments for chronic pain conditions such as back pain, arthritis pain, cancer pain, neuropathic pain and fibromyalgia pain. Chronic pain is generally defined as any pain lasting more than 12 weeks. The chronic pain market comprises of pharmaceuticals like antidepressants, anti-seizure, NSAIDs, opioids and other drugs as well as non-pharmaceutical treatments including medical devices, physiotherapy and psychological therapeutic approaches. Devices used for pain management include neurostimulation devices, analgesic infusion pumps and ablation devices.
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
